The Cancer

focal cryoablation; focal treatment; cryoablation; cryotherapy; focal cryotherapy; cryosurgery; prostate cancer

INTRODUCTION

In the era of PSA screening, prostate cancer faced a dramatic increase in incidence. Early detection of asymptomatic disease leads to majority of patients being diagnosed at earlier clinical stages (¹). Currently, up to 90% of the patients diagnosed with prostate cancer in United States have localized disease (²). With modern cancer treatments available, patients and physicians struggle to decide among available treatment options with curative intent. Physicians and patients need to select which treatment modality will treat their cancer without morbidity. Thus, we had a surge of the development of less invasive treatments including laparoscopic and robotic surgeries, and ablative therapy.

Overtreatment and Less Invasive aggressive therapy for Localized Prostate cancer

In the PSA era, overtreatment of prostate cancer patients became a clinical and public health controversy. Therefore, active surveillance became popular and recommended in selected localized, low and intermediate prostate cancer patients (³, ⁴). Conversely, the lack of aggressive treatment after diagnosis of cancer may lead 50% of patients enrolled in watchful waiting cross to active treatment in a period of 5 years post-diagnosis (⁵, ⁶). Another issue is the limitations of ultrasound guided biopsies that cannot accurately grade the disease since the pathological upgrade of prostate specimens after radical prostatectomy is often seen when compared to pre-operative pathological findings (⁷-¹⁰).

In addition one cannot forget the emotional burden of the diagnosis of cancer and anxiety that frequently drives patients in active surveillance to seek for active treatment (¹¹). Currently, aggressive treatment may be necessary in patients with moderate/high-risk prostate cancer (³, ⁴).

Unfortunately, there is no cookie cutter solution for prostate cancer patients and individual preferences, beliefs, and social economic status play a pivotal role in patient’s decision making. Minority status, age, marital status, race, and D’Amico risk stratification are associated with patients who opt for less invasive treatment of localized prostate cancer (¹², ¹³).

The American (AUA) and European Urological Associations (EAU) recommend active surveillance and monotherapy treatment options for men with low-risk prostate cancer. While, for patients with intermediate or high risk prostate cancer, the mono or multimodal therapies may achieve better cancer control (³, ⁴).

In 2008, the AUA’s best practice statement on cryosurgery affirmed that cryosurgery is an option for patients with organ confined disease (¹⁴).

The advent of new generation cryotechnology machines, smaller probes with better control of the ice ball and better ultrasound definition made prostate cryoablation well-established and accepted worldwide technique to treat localized prostate cancer minimizing risk of urinary incontinence, erectile dysfunction, and recto-urethral fistulas when compared to earlier experiences (¹⁵-¹⁷).

Potentially, targeted or focal cryoablation of prostatic tumors may treat localized diseases decreasing the morbidity and reducing the number patients over treated with aggressive and debilitating treatments (¹⁴). The concept of targeting the cancer inside the prostate without collateral damage to the rectum, neurovascular bundles, bladder neck, and urinary sphincter is attractive and evolving (¹⁸, ¹⁹).

Controversy still exists regarding the benefits of aggressive therapy (radical prostatectomy) versus non-aggressive management of prostate cancer and the lack of survival benefits with surgery, as seen in The Prostate Cancer Intervention Versus Observation Trial (PIVOT) and the Scandinavian Prostate Cancer Group SPCG-4 trial (²⁰, ²¹).

Critics of focal cryoablation of localized prostate tumors argue that prostate cancer is known to be multifocal. A dominant lesion is often accompanied by other smaller low-grade lesions. However, with novel genetic profiling tests and better understanding of the index lesion we can better select patients for this specific treatment modality. The index lesion is associated with the highest Gleason grade, presence of lymph node metastasis, genetic profiling and other pathological determinants of progression (²²-²⁵).

Recently, the Cryo Online Data (COLD) Registry reported 1160 patients that had focal prostate cryoablation, showing an increase from 2.1% (1999) to 38.2% (2007) of cryoablation patients that received this targeted therapy for localized prostate cancer (²⁶).

The biochemical recurrence-free survival (ASTRO criteria) for patients stratified by risk group after focal therapy was similar to whole gland cryoablation at two years clinical follow-up (²⁶). Pathological recurrence rates during follow-up were also similar when comparing focal cryoablation with whole gland cryoablation. Since the eligibility criteria for focal cryotherapy was not defined and this study was done retrospectively, further analysis should be done.

Similarly, a small prospective study evaluating focal cryoablation (hemi-ablation) was conducted in 56 patients with unilateral low-grade prostate cancer. A total of 86% of the patients had negative biopsies during the follow-up (²⁷).

Why cryoablation has a bad reputation?

During early cryoablation experience, the use of liquid nitrogen and inability to create a controlled ice ball, archaic ultrasound technology and absence of urethral warmers resulted in high incidence of rectourethral fistula and urinary incontinence. Moreover, these events occurred in whole gland cryoablation and in post-radiation salvage therapy patients (¹⁵, ¹⁶, ²⁶, ²⁸). Currently, these complications are less frequent due to the new technology and they seldom during focal cryotherapy (²⁶). In addition, patients that had normal erectile function before focal cryoablation were more likely to maintain function after the focal treatment (58%) when compared to whole gland treatment (32.3%) (²⁶).

Post-Radiation Targeted Therapy

While salvage treatment of failed post-radiotherapy patients can result in high complication rates associated with surgery and miss the opportunity for curative treatment (²⁹). The complication rates for robotic-assisted salvage radical prostatectomy were as high as 47% with Clavien III-V in 35% of the patients. Within three years of follow-up, potency was maintained in only 23% of the patients and urinary control was achieved in only 45% of the patients (³⁰). Open radical prostatectomy also had high complication rates with urinary continence rated ranging from 36 to 81%, erectile function in less than 30%, and biochemical recurrence-free probability from 37 to 55% within 5 years. The estimated cancer-specific survival at 10 years ranged from 70 to 83% (³¹). Salvage focal cryotherapy achieved 95.3%, 72.4%, and 46.5% biochemical-free survival at 1, 3, and 5 years of follow-up (³²). A total of 3.3% of patients experienced rectourethral fistula, 5.5% experienced incontinence, and 50% of the patients maintained sexual function after salvage treatment (³²). The oncological outcomes of focal prostate cryoablation reported are comparable to open salvage radical prostatectomy with improved functional outcomes and lower complication rates. Sexual function after salvage focal cryotherapy has shown to be better when compared to whole gland salvage cryotherapy (³²).

It appears that the cryoablative technology is efficient even in cases of radiation failure prostate cancer. Salvage whole gland cryoablation and focal cryoablation seem as reasonable options for curative treatment of this select group of patients (³²-³⁵).

FUTURE

The options for the management of prostate cancer are transitioning to active surveillance and less invasive procedures (¹², ¹⁵, ¹⁶, ³⁶-³⁸). The effectiveness of the treatment of localized prostate cancer will rely on accurate detection and localization of the prostate cancer cells in the body and the clinical relevance of these findings so we can efficiently select the right patients to the right treatment.

Three-dimensional computer models, alternative biopsy techniques, target biopsies, and tumor markers are potential tools that can be used to aid this task (³⁷, ³⁹-⁴³).

We are still trying to understand the effects of the U.S. Preventive Services Task Force (USPTF) report discouraging PSA screening due to the imbalance of risks outweighing the benefits of prostate cancer diagnosis (⁴⁴). However, it is our hope that the pre-PSA era of advanced stage prostate cancer at the time of diagnosis does not return to haunt us.

Despite the lack of randomized clinical trials comparing focal cryoablation of the prostate with other treatment modalities, the oncological and functional outcomes are pointing to a promising therapy for patients with localized disease (²⁶, ³³, ³⁵, ⁴⁵). One should not considered the focal cryoablation as “placebo” for patients that are good candidates for active surveillance but elect for an aggressive treatment option. The reality is that what we believe to be an ideal candidate for active surveillance may have a more aggressive cancer cell population or radiation resistant cells that can be treated with cryoablative technology.

Finally, the anxiety caused by the word cancer can affect the quality of life of patients and set stage to a well-known clinical challenge; “the sword of Damocles”, patients that cannot enjoy life with the idea of untreated cancer.

However, data are sought after to understand the selection of optimal patients for focal cryotherapy.

CONCLUSIONS

Targeted or focal cryoablation of prostate tumors is a promising curative therapy for localized prostate cancer. Oncological outcome is comparable to available standard therapies with better functional outcomes and reduced morbidity when compared to whole gland cryotherapy. Challenges to effectively select the optimal patient for focal cryotherapy will depend on complete understanding of clinical relevance and imaging methodologies to detect localized prostate cancer cells in the body.

REFERENCES

• ¹
  Neppl-Huber C, Zappa M, Coebergh JW, Rapiti E, Rachtan J, Holleczek B, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol. 2012;23:1325-34.
• ²
  Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Câncer statistics, 2006. CA Cancer J Clin. 2006;56:106-30.
• ³
  Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124-37.
• ⁴
  Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106-31.
• ⁵
  Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003;21:4001-8.
• ⁶
  Wu H, Sun L, Moul JW, Wu HY, McLeod DG, Amling C, et al. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol. 2004;171:1111-6.
• ⁷
  Tilki D, Schlenker B, John M, Buchner A, Stanislaus P, Gratzke C, et al. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series. Urol Oncol. 2011;29:508-14.
• ⁸
  Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, et al. SEARCH Database Study Group. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol. 2008;179:523-7;discussion 527-8.
• ⁹
  Tanaka N, Fujimoto K, Hirayama A, Nakai Y, Chihara Y, Anai S, et al. Calculated tumor volume is an independent predictor of biochemical recurrence in patients who underwent retropubic radical prostatectomy. Adv Urol. 2012;2012:204215.
• ¹⁰
  Tanaka N, Fujimoto K, Hirayama A, Torimoto K, Okajima E, Tanaka M, et al. Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. Int J Clin Oncol. 2011;16:553-9.
• ¹¹
  Simpkin AJ, Tilling K, Martin RM, Lane JA, Hamdy FC, Holmberg L, et al. Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. Eur Urol. 2015;21. [Epub ahead of print]
• ¹²
  Kim FJ, Werahera PN, Sehrt DE, Gustafson D, Silva RD, Molina WR. Ethnic minorities (African American and Hispanic) males prefer prostate cryoablation as aggressive treatment of localized prostate cancer. Can J Urol. 2014;21:7305-11.
• ¹³
  Denberg TD, Kim FJ, Flanigan RC, Fairclough D, Beaty BL, Steiner JF, et al. The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma. Med Care. 2006;44:1137-41.
• ¹⁴
  Richard J. Babaian, Bryan Donnelly, Duke Bahn, John G. Baust, Martin Dineen, David Ellis, et al. Best practice policy statement on cryosurgery for the treatment of localized prostate cancer. Available at: https://www.auanet.org/education/guidelines/cryosurgery.cfm: American Urological Association; 2008 [cited 2015 2015/02/16].
  » https://www.auanet.org/education/guidelines/cryosurgery.cfm:
• ¹⁵
  da Silva RD, Jaworski P, Gustafson D, Nogueira L, Molina W, Kim FJ. How I do it: prostate cryoablation (PCry). Can J Urol. 2014;21:7251-4.
• ¹⁶
  Kim FJ, Cerqueira MA, Almeida JC, Pompeo A, Sehrt D, Calheiros JM, et al. Initial brazilian experience in the treatment of localized prostate cancer using a new generation cryotechnology: feasibility study. Int Braz J Urol. 2012;38:620-6.
• ¹⁷
  Maccini M, Sehrt D, Pompeo A, Chicoli FA, Molina WR, Kim FJ. Biophysiologic considerations in cryoablation: a practical mechanistic molecular review. Int Braz J Urol. 2011;37:693-6.
• ¹⁸
  Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol. 2007;4:632-42.
• ¹⁹
  Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, et al. Transatlantic Consensus Group on Active Surveillance and Focal Therapy for Prostate Cancer (appendix). Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int. 2012;109:1636-47.
• ²⁰
  Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled Trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30:81-7.
• ²¹
  Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370:932-42.
• ²²
  Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, et al. Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol. 2012;30:4294-6.
• ²³
  Ahmed HU, Arya M, Freeman A, Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol. 2012;13:e509-17.
• ²⁴
  Hall GS, Kramer CE, Epstein JI. Evaluation of radical prostatectomy specimens. A comparative analysis of sampling methods. Am J Surg Pathol. 1992;16:315-24.
• ²⁵
  Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol. 2010;41:781-93.
• ²⁶
  Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2012;109:1648-54.
• ²⁷
  Durand M, Barret E, Galiano M, Rozet F, Sanchez-Salas R, Ahallal Y, et al. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int. 2014;113:56-64.
• ²⁸
  Lambert EH, Bolte K, Masson P, Katz AE. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology. 2007;69:1117-20.
• ²⁹
  Hautmann RE. Salvage radical prostatectomy. Urologe A. 2006;45:1260-5.
• ³⁰
  Yuh B, Ruel N, Muldrew S, Mejia R, Novara G, Kawachi M, et al. Complications and outcomes of salvage robot-assisted radical prostatectomy: a single-institution experience. BJU Int. 2014;113:769-76.
• ³¹
  Rosoff JS, Savage SJ, Prasad SM. Salvage radical prostatectomy as management of locally recurrent prostate cancer: outcomes and complications. World J Urol. 2013;31:1347-52.
• ³²
  Li YH, Elshafei A, Agarwal G, Ruckle H, Powsang J, Jones JS. Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry. Prostate. 2015;75:1-7.
• ³³
  Spiess PE, Levy DA, Pisters LL, Mouraviev V, Jones JS. Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry. World J Urol. 2013;31:1321-5.
• ³⁴
  Spiess PE, Given RW, Jones JS. Achieving the ‘bifecta’ using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On-Line Data (COLD) registry data. BJU Int. 2012;110:217-20.
• ³⁵
  Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180:559-63; discussion 563-4.
• ³⁶
  Miano R, Kim FJ, De Nunzio C, Mauriello A, Sansalone S, Vespasiani G, et al. Morphological evaluation of the male external urethral sphincter complex by transrectal ultrasound: feasibility study and potential clinical applications. Urol Int. 2012;89:275-82.
• ³⁷
  Miano R, De Nunzio C, Kim FJ, Rocco B, Gontero P, Vicentini C, et al. Transperineal versus transrectal prostate biopsy for predicting the final laterality of prostate cancer: are they reliable enough to select patients for focal therapy? Results from a multicenter international study. Int Braz J Urol. 2014;40:16-22.
• ³⁸
  Autorino R, Kaouk JH, Yakoubi R, Rha KH, Stein RJ, White WM, et al. Urological laparoendoscopic single site surgery: multi-institutional analysis of risk factors for conversion and postoperative complications. J Urol. 2012;187:1989-94.
• ³⁹
  Narayanan R, Werahera PN, Barqawi A, Crawford ED, Shinohara K, Simoneau AR, et al. Adaptation of a 3D prostate cancer atlas for transrectal ultrasound guided target-specific biopsy. Phys Med Biol. 2008;53:N397-406.
• ⁴⁰
  Werahera PN, Crawford ED, La Rosa FG, Torkko KC, Schulte B, Sullivan HT, et al. Anterior tumors of the prostate: diagnosis and significance. Can J Urol. 2013;20:6897-906.
• ⁴¹
  Crawford ED, Wilson SS, Torkko KC, Hirano D, Stewart JS, Brammell C, et al. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int. 2005;96:999-1004.
• ⁴²
  Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, et al. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013;73:778-87.
• ⁴³
  Werahera PN, Sullivan K, La Rosa FG, Kim FJ, Lucia MS, O’Donnell C, et al. Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume. Int J Clin Exp Pathol. 2012;5:892-9.
• ⁴⁴
  Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-34.
• ⁴⁵
  Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180:554-8.

Publication Dates

• Publication in this collection
  jan-feb 2015